Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
The Personalized Biotech Flywheel Cathie Wood Built Is Still a Winning Bet Today
08:52am, Friday, 03'rd Apr 2026
What if the biggest winners in biotech weren't the ones promising miracle cures, but the ones quietly supplying the picks and shovels — data that makes those cures possible?
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
06:50pm, Thursday, 02'nd Apr 2026
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.51, moving +1.43% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider
07:01pm, Wednesday, 01'st Apr 2026
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $48.81, denoting a +2.61% move from the preceding trading day.
A Turning Point For Crispr Therapeutics As Commercial Growth Accelerates
12:43pm, Wednesday, 01'st Apr 2026
CRISPR Therapeutics AG (CRSP) is rated Buy, with a 12-month price target of $64.58, driven by CASGEVY's commercial ramp and a robust pipeline. CASGEVY's increasing patient initiations and revenue grow
I Expect Crispr Therapeutics To Break Out As 2026 Revenue Exceeds Expectations
08:30am, Tuesday, 31'st Mar 2026
Crispr Therapeutics AG is positioned for a revenue inflection as Casgevy ramps in 2026, following earlier FDA/EMA approvals for SCD and TDT. Analysts are underestimating the Casgevy revenue ramp. CRSP
Samarth Kulkarni Sells 10,020 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock
04:22am, Friday, 27'th Mar 2026
CRISPR Therapeutics AG (NASDAQ: CRSP - Get Free Report) CEO Samarth Kulkarni sold 10,020 shares of the company's stock in a transaction on Monday, March 23rd. The shares were sold at an average price
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today
06:51pm, Wednesday, 25'th Mar 2026
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $47.09, moving +1.42% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Tuesday, 24'th Mar 2026
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Inclusion in U.S. CRSP® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, including the world's largest mutual fund Expands market p
CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now?
01:30pm, Monday, 23'rd Mar 2026
CRISPR recently raised nearly $600 million through a private offering, which weighed down its share price. The company has an approved therapy in Casgevy, but its business remains deeply unprofitable.
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of “Hold” from Analysts
02:56am, Monday, 23'rd Mar 2026
CRISPR Therapeutics AG (NASDAQ: CRSP - Get Free Report) has been assigned an average rating of "Hold" from the eighteen research firms that are covering the company, MarketBeat.com reports. Two resear
Is CRISPR Therapeutics Stock a Buy Now?
08:00am, Friday, 20'th Mar 2026
CRISPR Therapeutics' lone approved product isn't generating much revenue yet. The company has made little clinical progress elsewhere in recent years.
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
06:50pm, Thursday, 19'th Mar 2026
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $46.93, representing a -1.59% change from its previous close.
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
07:00pm, Wednesday, 18'th Mar 2026
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $47.69, representing a -4.79% change from its previous close.
From $49 to $110: Why Piper Sandler Thinks CRSP Can More Than Double From Here
12:16pm, Tuesday, 17'th Mar 2026
CRISPR Therapeutics (NASDAQ:CRSP) has had a rough stretch lately.
